Global RNA Therapeutics Market Grows Steadily at a CAGR of 9.37%

Introduction

Straits Research released its highly anticipated report, “Global RNA Therapeutics Market Size & Outlook, 2026-2034”. According to the study, the global market size is valued at USD 20.32 billion in 2025 and is projected to expand to USD 45.35 billion by 2034, registering a compound annual growth rate (CAGR) of 9.37%.

Market Dynamics

The growth of the global RNA therapeutics market is strongly driven by the emergence of next-generation RNA platforms, the surge in approvals of RNAi therapies, and the rapid adoption of personalized RNA treatments for rare and genetic diseases. Advancements in RNA delivery technologies are further accelerating adoption across therapeutic areas due to their safety and efficiency. For example, novel delivery methods such as exosomes and peptide-based carriers are enabling RNA treatments such as Alnylam’s Givlaari and Amvuttra to effectively reach complex tissue structures in neurological and cancer conditions, boosting demand for approved RNA therapeutics. Furthermore, growing government-backed funding for RNA biomanufacturing facilities, such as the UK’s CPI RNA Centre of Excellence, is enhancing domestic capabilities and supporting large-scale innovation.

However, the market faces restraints such as high development and manufacturing costs, with raw material expenses accounting for nearly 60% of mRNA production, making large-scale affordability challenging. Furthermore, maintaining specialized cold chain logistics adds to cost and supply barriers. On the other hand, expanding RNA applications beyond vaccines into metabolic, cardiovascular, and central nervous system diseases presents new opportunities for market growth.

Market Highlights

• Type: The RNA interference (RNAi) segment is expected to register the fastest CAGR of 10.2% in 2026-2034.
• Application: The oncology segment dominated the market in 2025 with a revenue share of 33.57%.
• End User: According to Straits Research, the hospitals & clinics segment dominated the market in 2025 and is estimated to grow at the fastest CAGR, owing to the increasing availability of marketed RNA drugs through hospital settings, and the establishment of specialty clinics for rare and oncology diseases.
• Regional Insights: North America held a dominant share of the global market, accounting for 43.79% share in 2025, owing to a surge in approval of new RNA therapies.

Competitive Players

1. Moderna, Inc.
2. Pfizer Inc.
3. Alnylam Pharmaceuticals, Inc.
4. Ionis Pharmaceuticals, Inc.
5. Sarepta Therapeutics, Inc.
6. Novartis AG
7. Sanofi
8. CureVac N.V.
9. Orna Therapeutics
10. Arrowhead Pharmaceuticals, Inc.
11. Suzhou Abogen Biosciences
12. CSPC Pharmaceutical
13. Dicerna Pharmaceuticals
14. Geron
15. Silence Therapeutics
16. Wave Life Sciences
17. ASCIDIAN THERAPEUTICS, INC.
18. Korro Bio, Inc.
19. Chimerna Therapeutics, Inc.
20. Replicate Biosciences
21. Others

Recent Developments

Segmentation

1. By Therapy Type (2026-2034)
   1. mRNA Therapeutics
   2. RNA interference (RNAi)
   3. Antisense oligonucleotides
   4. Others
2. By Application (2026-2034)
   1. Oncology
   2. Infectious Diseases
   3. Genetic Diseases
   4. Ophthalmology
   5. Cardiovascular Diseases
   6. Others
3. By End User (2026-2034)
   1. Hospitals & Clinics
   2. Research Institutes
   3. Others